Cover Kidney News
Volume/Issue:
Volume 11: Issue 8
Page:
15–16
Publication Date:
01 Aug 2019
Online Publication Date:
05 Aug 2019
  • 1.

    Pfeffer MA, et al.. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–2257.

  • 2.

    Mann JFE, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839–848.

  • 3.

    Marso SP, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–322.

  • 4.

    Tuttle KR, et al.. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605–617.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Marso SP, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834–1844.

  • 6.

    American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S90–S102.

    • Search Google Scholar
    • Export Citation
  • 7.

    Tuttle KR, et al.. CKD outcomes in type 2 diabetes and moderate-to-severe CKD treated with dulaglutide versus insulin glargine: AWARD-7 [Poster]. JASN Kidney Week Edition Abstract Supplement 2018. 2018; Poster TH-OR033.

    • Search Google Scholar
    • Export Citation
  • 8.

    Mann JFE, et al.. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation 2018; 138:2908–2918.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Sun F, et al.. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110:26–37.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Potts JE, et al.. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10:e0126769.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Vilsboll T, et al.. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344:d7771.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Renal Physiol 2018; 315:F1519–F1525.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Tanaka T, et al.. The potential for renoprotection with incretin-based drugs. Kidney Int 2014; 86:701–711.

Editorial Type:
Features

Emergence of GLP-1 Receptor Agonists as a Therapy for Diabetic Kidney Disease

Radica Z. Alicic1, Emily J. Cox1, and Katherine R. Tuttle1
  • 1 Radica Z. Alicic, MD, FHM, FACP, is with Providence Health Care and the University of Washington School of Medicine. Emily J. Cox, PhD, is with Providence Health Care. Katherine R. Tuttle, MD, FACP, FASN, FNKF, is with Providence Health Care, the Kidney Research Institute, the Institute of Translational Health Sciences, and the University of Washington School of Medicine.
Volume/Issue:
Volume 11: Issue 8
Publication Date:
01 Aug 2019
Page:
15–16
Restricted access

A multitude of clinical effects beyond glycemic control have placed glucagon-like peptide-1 (GLP-1) receptor agonists front and center in the fields of diabetology, cardiology, and nephrology. These incretin-based antihyperglycemic agents reduce the risk of new or worsening kidney disease and decrease the risk of cardiovascular death and atherosclerotic events (1–5). In the wake of these findings, the American Diabetes Association Standards of Care for treatment of hyperglycemia in type 2 diabetes now state that GLP-1 receptor agonists with proven cardiovascular benefits (liraglutide > semaglutide > exenatide extended release) should be added to the therapeutic regimen if
Save